AT 56, Catalog: 2592

Alternate Names 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine

Appearance White solid

CAS # 162640-98-4

Molecular Formula C₂₅H₂₇N₅

Molecular Weight 397.52

Purity ≥ 98% by HPLC

Solubility DMSO (>15 mg/ml)

SMILES C1CN(CCC1=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CCCCC5=NNN=N5

InChi InChI=1S/C25H27N5/c1-3-9-22-19(7-1)12-13-20-8-2-4-10-23(20)25(22)21-14-17-30(18-15-21)16-6-5-11-24-26-28-29-27-24/h1-4,7-10,12-13H,5-6,11,14-18H2,(H,26,27,28,29)

InChi Key LQNGMDUIRLSESZ-UHFFFAOYSA-N

PubChem CID 11741525

Storage Conditions -20°C

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

AT-56 is a selective, competitive, and highly bioavailable inhibitor of L-PGDS (lipocalin-type prostaglandin D synthase) (Ki = 75 µM). It inhibits the production of PGD2 by L-PGDS purified from human CSF and recombinant mouse cells with an IC₅₀ value of 95 µM. At concentrations as high as 100 µM in vitro or 30 mg/kg in vivo, AT-56 does not affect the production of PGE2, PGF2α, or H-PGDS-catalyzed PGD2.